Salute e Benessere

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…

Attachments pdmr-notification-C-Ackermann-option exercise-oct 2025pdmr-notification-C-Ackermann-sale of shares-oct 2025
Nasdaq GlobeNewswire
14/10/2025

Inventiva Announces the Implementation of a New ATM Program

Daix (France), New York City (New York, United States), October 14, 2025 –Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “ Registration Statement ”) with the Securities and Exchange Commission (“ SEC ”). The Registration Statement...
Nasdaq GlobeNewswire
14/10/2025

GCC Medical Tourism Market to Reach USD 889.97 million by 2032, Growing At An…

The Gulf Cooperation Council (GCC) medical tourism sector is witnessing remarkable growth, positioning the region as a global hub for advanced healthcare services. The GCC Countries Medical Tourism Market is projected to expand from USD 367.41 million in 2024 to USD 889.97 million by 2032, reflecting a CAGR of 10.26% during 2024–2032. The Gulf Cooperation Council (GCC) medical tourism sector is witnessing remarkable growth, positioning the region as a global hub for advanced healthcare…
PR Newswire
14/10/2025

Spineway : Revenue growth in the third quarter

SPINEWAY Revenue growth in the third quarter In thousands of euros 20252024Change as a % Q3 revenue3,0452,575 +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M revenue8,6189,110 -5% Unaudited consolidated data The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, benefited, in line with its expectations, from a deferral of orders from major accounts to the third...
Nasdaq GlobeNewswire
14/10/2025

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l’Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of €2,454,937,946 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
14/10/2025

THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE…

THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01 THX Pharma (Theranexus) and Exeltis have reached a pivotal milestone, setting the stage for the regulatory submission of TX01 for Gaucher and Niemann-Pick type C diseases Lyon, France – Madrid, Spain – October 14, 2025 – 6…
Actusnews Wire
14/10/2025

Sequana Medical alfapump® System Highlighted at SIR EDGE 2025 Conference

, Oct.14, 2025(GLOBE NEWSWIRE) --Ghent, Belgium – 14 October 2025–Sequana Medical NV (Euronext Brussels: SEQUA(the“Company”or“Sequana Medical” ), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced that thealfa pump System was highlighted in a presentation at the Society of Interventional Radiology’s SIR EDGE 2025 conference in San Diego. The presentation titled “Not the Alpha Male, the Alfapump!” showcased...
Nasdaq GlobeNewswire
14/10/2025

Breast Fillers Market to Reach $728.7 million, Globally, by 2034 at 6.3% CAGR…

Breast fillers are gaining popularity due to their customizable results, fewer complications, and increasing demand for natural looking enhancements. Advancements in filler technology and growing aesthetic consciousness, particularly among younger women, are driving market growth globally. Breast fillers are gaining popularity due to their customizable results, fewer complications, and increasing demand for natural looking enhancements. Advancements in filler technology and growing aesthetic...
PR Newswire
14/10/2025

Molecular Cytogenetics Market worth $1.43 billion in 2030 7.1% CAGR |…

Browse in-depth TOC on "Molecular Cytogenetics Market" Browse in-depth TOC on "Molecular Cytogenetics Market" 139 - Tables 45 - Figures 235 - Pages By product & service,the molecular cytogenetics market is segmented into kits & reagents, instruments, consumables, and software & services. Kits & reagents are expected to record the fastest growth during the forecast period. This surge is driven by their significant role in research, diagnostics, and...
PR Newswire
14/10/2025

Conformal Medical Announces First Patient Enrollment in the E.U. for CONFORM…

The CONFORM Pivotal Trial is evaluating the CLAAS® AcuFORM™ LAAO device, a novel foam-based implant designed to provide a simplified, anatomy-conforming solution for stroke prevention in patients with non-valvular atrial fibrillation (AFib). The CONFORM Pivotal Trial is evaluating the CLAAS ®AcuFORM ™LAAO device, a novel foam-based implant designed to provide a simplified, anatomy-conforming solution for stroke prevention in patients with non-valvular atrial fibrillation (AFib). ...
PR Newswire
14/10/2025

Medical Second Opinion Market Size to Reach USD 12.7 Billion by 2031 Amid Rising…

Digital health platforms, telemedicine, artificial intelligence (AI), and global specialist networks are enabling faster, more accurate, and more affordable access to expert medical opinions-making this market one of the fastest-growing sectors in healthcare services. Digital health platforms, telemedicine, artificial intelligence (AI), and global specialist networks are enablingfaster, more accurate, and more affordableaccess to expert medical opinions-making this market one of the...
PR Newswire
14/10/2025

/C O R R E C T I O N -- iOnctura/

Lead investigator, Davide Melisi, M.D., Ph.D, Associate Professor of Medical Oncology, and Director of the Digestive Molecular and Clinical Oncology Research Unit, University of Verona, and Investigational Cancer Therapeutics Clinical Unit at the University Hospital of Verona, Verona, Italy said, "These early findings with cambritaxestat are encouraging. Clinical activity alongside a manageable safety profile is particularly meaningful in a disease as aggressive and fibrotic as metastatic…
PR Newswire
14/10/2025

Quotient Sciences and Biorasi partner to accelerate early phase clinical trials…

The partnership will combine Quotient Sciences' expertise inearly clinical developmentwith Biorasi's global patient recruitment capabilities to provide biotech and pharma Sponsors with a simplified, efficient pathway from Investigational New Drug (IND) to proof-of-concept (POC) with seamless transitions from healthy volunteers into patient groups within first-in-human (FIH) Phase I/IIa clinical trials. Sponsors will benefit from Quotient Sciences' clinical pharmacology expertise,...
PR Newswire
14/10/2025

Pictor's Proteomics Platform Offers Promising Advancement for Detecting…

The research, conducted with funding from New Zealand's Ministry for Primary Industries and the University of Melbourne, demonstrates excellent analytical performance and a high level of agreement with existing methods. The PictVet™ assay achieved a Positive Percent Agreement (PPA) of 100%, a Negative Percent Agreement (NPA) of 98.4%, and an overall agreement of 98.9% compared to the IDvet ELISA. This performance is supported by a unique multiplex design that uses two distinct Mycoplasma bovis…
PR Newswire
14/10/2025

India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to…

At the heart of this initiative is the Hyundai Centre for Cancer Genomics, housed at IIT Madras. It will also serve as a collaborative hub for clinicians, researchers, pharmaceutical scientists, and global partners, contributing to international efforts such as the International Cancer Genome Consortium (ICGC) and WHO's International Agency for Research on Cancer (IARC). At the heart of this initiative is the Hyundai Centre for Cancer Genomics, housed at IIT Madras.It will also serve as a...
PR Newswire
14/10/2025

KVP International Strengthens Its Global Position with Rapid EU and Latin…

The company, already serving over 30 countries worldwide, continues to report record global sales and strong growth across both established and emerging markets. The company, already serving over 30 countries worldwide, continues to report record global sales and strong growth across both established and emerging markets. Over the past year, KVP has added eight (8) new distributor partners across the European Union, three (3) new major distributors inLatin America, expanded its product...
PR Newswire
14/10/2025

Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to…

The REMBRANDT trial, sponsored by NewAmsterdam Pharma (Nasdaq: NAMS), is a placebo-controlled, double-blind, randomized trial designed to assess the efficacy of obicetrapib and ezetimibe fixed dose combination (FDC) on coronary plaque burden. Obicetrapib is an investigational cholesteryl ester transfer protein (CETP) inhibitor that has shown to lower low-density lipoprotein cholesterol (LDL-C) in three Phase 3 clinical trials. Favorable changes in noncalcified coronary atherosclerotic plaque…
PR Newswire
14/10/2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Company Announcement Net sales of DARZALEX ®in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN, Denmark; October 14, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj , sold under the...
Nasdaq GlobeNewswire
14/10/2025

Digital Health Market Segmentation: Key Technologies, Growth Factors, and Market…

Transparency Market Research
14/10/2025

11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients…

The act of engaging with toys holds significant therapeutic value for children, fostering imagination, promoting emotional well-being, and supporting healthy development. In these workshops employees created superhero toys from scratch, a powerful symbol of the strength and resilience of young patients navigating their treatment journeys. By engaging in this creative and hands-on activity, Bristol Myers Squibb employees reaffirmed their commitment to supporting patients beyond medicine, bringing…
PR Newswire
14/10/2025

iOnctura debuts cambritaxestat (IOA-28G) clinical data in patients with…

The Phase Ib dose escalation study, AION-02 (NCT05586516) evaluated cambritaxestat in combination with standard-of-care chemotherapy GnP in patients with previously untreated mPDAC. Sixteen patients received cambritaxestat orally, twice daily at doses of 100 mg (n=4), 200 mg (n=4), 400 mg (n=5) and 800 mg (n=3). GnP was administered by IV infusion, weekly for three weeks of a four-week cycle. The Phase Ib dose escalation study, AION-02 (NCT05586516 )evaluated cambritaxestat in combination...
PR Newswire
14/10/2025

Orion publishes Interim Report for January–September 2025 and holds a webcast on…

ORION CORPORATIONPRESS RELEASE14 OCTOBER 2025 at 11.15 EEST Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025 Orion will publish Interim Report for January–September 2025 on Tuesday, 28 October 2025 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website atwww.orionpharma.com/investorsafter publishing. Webcast and conference call A webcast and a...
Nasdaq GlobeNewswire
14/10/2025

From Silicon Valley to Mainstream Medicine: How elegant hoopoe 'Longevity…

What began as an elite trend among tech executives and athletes has evolved into a fundamental shift in how people approach health. Analysis of 61+ million social posts reveals biohacking has gone mainstream, with consumer conversations around blood sugar management and personalised supplementation rising 30% and 27% annually (source). What began as an elite trend among tech executives and athletes has evolved into a fundamental shift in how people approach health. Analysis of 61+…
PR Newswire
14/10/2025

ILIKOS and Zapyrus have partnered to equip MedTech CRO business development…

In a market where innovation cycles are tightening and competition for customer attention is fierce, business development teams must rely on more than just instinct. It is critical that they utilize a data-driven, execution-ready approach combined with consistency, persistence and industry knowledge. This partnership merges ILIKOS' recognized expertise in building and implementing tailored business development methodologies with Zapyrus' leading sales and market intelligence platform, which…
PR Newswire
14/10/2025
Altri  Comunicati